ANI PHARMACEUTICALS INC ANIP revenue by segment, product and geography
In its fiscal year ending 2025-12-31, ANI PHARMACEUTICALS INC reported revenue across 9 products and services; the largest, Total Sales Of Rare Disease And Brands, was $484M (+64.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Total Sales Of Rare Disease And Brands$484Mshare n/a+64.4% yoy
- Total Sales Of Rare Disease Pharmaceutical Products$423Mshare n/a+84.1% yoy
- Total Sales Of Generics And Other$399Mshare n/a+24.8% yoy
- Sales Of Generic Pharmaceutical Products$384Mshare n/a+27.6% yoy
- Sales Of Cortrophin Gel$348Mshare n/a+75.6% yoy
- Sales Of ILUVIEN And YUTIQ$74.9Mshare n/a+137.6% yoy
- Sales Of Established Brands$61.3Mshare n/a-5.3% yoy
- Unapproved Products$24.1Mshare n/a+7.6% yoy
- +1 more member in the filing
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- United States$852M96.5%+40.9% yoy
- Outside the United States$30.9M3.5%+229.4% yoy
Members sum to the consolidated $883M for this period.
- Total Sales Of Rare Disease And Brands$128Mshare n/a+36.3% yoy
- Total Sales Of Generics And Other$109Mshare n/a+6.0% yoy
- Sales Of Generic Pharmaceutical Products$105Mshare n/a+6.8% yoy
- Total Sales Of Rare Disease Pharmaceutical Products$94.4Mshare n/a+36.9% yoy
- Sales Of Cortrophin Gel$75.1Mshare n/a+42.1% yoy
- Sales Of Established Brand Royalties And Other Revenues$21.5Mshare n/ano prior
- +4 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.